Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a dual N-methyl-D-aspartate receptor antagonist and sigma-1 agonist for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores. The company is also involved in Phase II clinical trial of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis, agitation in patients with Alzheimer’s disease, and levodopa-induced-dyskinesia in Parkinson’s disease. In addition, it is developing AVP-786, a Phase II clinical trial product for the treatment of major depressive disorder; and AVP-825, an investigational drug-device combination product consisting of low-dose sumatriptan powder for the acute treatment of migraine. The company has a license agreement with Concert Pharmaceuticals, Inc. to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurologic and psychiatric disorders, as well as rights to other deuterium-modified dextromethorphan compounds; and a license agreement with OptiNose AS for the development and commercialization of a novel breath powered intranasal delivery system to treat acute migraine. Avanir Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Aliso Viejo, California. Avanir Pharmaceuticals, Inc. operates as a subsidiary of Otsuka America, Inc.